Role of CES1 in lung blood vessel health and PAH biology
Official title: The Role of the CES1 in the Pathogenesis of Pulmonary Arterial Hypertension
Funded at Stanford University · NIH-11332306 · Data updated 2026-11-12
This NIH grant explores how a liver enzyme, CES1, helps lung blood vessels stay healthy and may drive pulmonary arterial hypertension in people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project start | August 23, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $528,478 |
| NIH project number | 5R01HL172449-03 |
| Project ID | NIH-11332306 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with PAH or those at risk who provide PMVEC samples or participate in related analyses.
✕Less likely to help
Patients without PAH or those not contributing samples or data related to PMVEC metabolism may not benefit directly.
What this research studies
The project focuses on how CES1 supports fatty acid flow between cellular compartments in lung microvessels. Researchers will study PMVECs from PAH patients and model how changes in CES1 affect energy use, blood vessel formation, and cell survival. The goal is to connect CES1 activity with the metabolic shifts seen in PAH and identify potential points to intervene. Results could point to new ways to slow or prevent vessel remodeling and right-heart strain in PAH patients.
Why it matters
Potential benefit: Understanding CES1’s role could lead to new strategies to protect lung vessels and reduce PAH progression.
How similar studies have gone: Earlier work links metabolic changes in PMVECs to PAH; this study extends that to CES1’s role, which is novel but builds on related mechanisms.
Where this research is happening
-
Stanford University
Stanford, United States Active
Researchers
- Principal investigator: De Jesus Perez, Vinicio a — Stanford University
- Study coordinator: De Jesus Perez, Vinicio a
Related research
Other NIH-funded projects on the same topics.
-
Understanding how blood flow and pressure affect lungs in PAH
This grant studies how abnormal blood flow and pressure contribute to pulmonary arterial hypertension and how patient factors shape these effects, with the aim of guiding better therapies.
-
Asporin as a double-targeted therapy and biomarker for a serious artery disease
This project tests a protein called asporin as both a treatment and a biomarker for pulmonary arterial hypertension (PAH) to help people with this life-threatening condition.
-
Platelets and fibroblasts linked to energy use in a hard-to-treat blood vessel disease
A research team at the University of Pittsburgh is studying how platelet energy metabolism and fibroblast glutamine use interact in systemic sclerosis-related pulmonary arterial hypertension to improve diagnosis and treatment.
-
A biatrial dual‑lumen catheter to help the heart and lungs in pulmonary arterial hypertension
A new double‑lumen catheter is being developed to unload the right side of the heart and protect the lungs for people with pulmonary arterial hypertension.
-
Endothelial inflammation and Src kinase in early pulmonary arterial hypertension
Researchers are studying how inflammation in the lining of blood vessels and a protein called Src kinase contribute to early lung artery remodeling in people with mild PAH.
-
Cardiopulmonary chip model to study right heart disease from high blood pressure in the lungs
A tiny heart-lung chip is being developed to understand why the right side of the heart enlarges in people with pulmonary arterial hypertension and to test targeted treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.